Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 18;11(6):471.
doi: 10.1038/s41419-020-2669-8.

The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape

Sara Bruschini  1 , Gennaro Ciliberto  2 , Rita Mancini  3
Affiliations

The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape

Sara Bruschini et al. Cell Death Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Quiescent cancer stem cells (CSCs) are able to evade immune surveillance and to promote tumour development.
At the site of the primary tumour, differentiated cancer cells and proliferating clusters of CSCs are subjected to immune cells clearance, instead CSCs that enter in a quiescent state are hidden. Isolated quiescent CSCs can enter the bloodstream and, evading the surrounding immune cells, are able to exit from dormancy and colonize the metastatic site. Metastatic outbreak can occur thanks to CSC plasticity and the acquisition of new immune evasive mechanisms. Like other types of treatments, CSCs are also refractory to immunotherapies leading to tumour relapse. These resistant cells overexpress key antigens or metabolic vulnerabilities that can be targeted by newer CSCs-specific immunotherapies or drugs directed to CSCs-associated pathways. Immunotherapies could be combined with targeted CSCs agents to both debulk the original tumour and eradicate any emerging resistant cells. However, the optimal timing, sequence and combination of these CSCs-specific, immune-based therapies requires further studies.
See this image and copyright information in PMC

References

    1. Laughney AM, et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat. Med. 2020;26:259–269. doi: 10.1038/s41591-019-0750-6. - DOI - PMC - PubMed
    1. Burnet M. Cancer—a biological approach I. The Processes of control. Br. Med. J. 1957;1:779–786. doi: 10.1136/bmj.1.5022.779. - DOI - PMC - PubMed
    1. Thomas, L. Cellular and Humoral Aspects of the Hypersensitive States (Hoeber-Harper, New York, 1959) pp. 529–533.
    1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002;3:991–998. doi: 10.1038/ni1102-991. - DOI - PubMed
    1. Agudo J, et al. Quiescent tissue stem cells evade immune surveillance. Immunity. 2018;48:271–284.e6. doi: 10.1016/j.immuni.2018.02.001. - DOI - PMC - PubMed

Publication types